NCT01811706 - Dalfampridine and Gait in Spinocerebellar Ataxias | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Spinocerebellar Ataxias Type 1Spinocerebellar Ataxias Type 2Spinocerebellar Ataxias Type 3Spinocerebellar Ataxias Type 6

Interventions

DRUG

Dalfampridine

Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks period

DRUG

Placebo

Placebo will be administered orally every 12 hours, for a 4 week period.

Trial Locations (1)

University of Florida, Gainesville